News InflaRx stock halves after it drops lead drug InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.
News InflaRx flatlines after skin disease drug flops in midstage ... Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug IFX-1 in a debilitating skin disease.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
